Allecra Therapeutics Successfully Enters Next Development Phase
Ready to start pivotal Phase III clinical trial
Allecra secures Series C ‚¬14M financing from existing shareholdersDr. Klaus Wilgenbus appointed as CEO and Dr. Mathias Knecht as second Managing Director
SAINT-LOUIS, France and WEIL AM RHEIN, Germany, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Allecra Therapeutics, an innovative clinical stage biopharmaceutical company, dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections is successfully en...